During Wednesday’s current trade, Midway Gold Corp (USA) (NYSEMKT:MDW)’s shares inclined 2.85% to $0.0830.
Midway Gold Corp. (MDW) remains in active talk about with its Senior Lender regarding planned partnerships, asset sale opportunities and debt refinancing opportunities. As formerly revealed, the terms of a waiver with regard to the Senior Debt have lapsed and the Company remains in talk about to obtain additional waivers. The Company’s Senior Lender has offered the Company with a notice alleging an event of default based on the non-monetary conditions which were formerly waived. The notice does not invoke or demand any specific remedies but states that it reserves all rights. Midway believes the notice is intended to document the conditions as viewed by Senior Lender and, while there can be no assurances, we will continue working toward maximizing value for our stakeholders by pursuing our planned alternatives.
Midway Gold Corp. engages in the acquisition, exploration, and development of gold and silver mineral properties in North America. The company holds interest in the Pan and Gold Rock Projects located along the prolific Battle Mountain/Eureka gold trend; the Spring Valley property, which is located in the Spring Valley Mining District, Pershing County, Nevada. It also has interest in the Tonopah property, which is located in Nye County, Nevada; and the Golden Eagle property located in the Eureka mining district in Ferry County, Washington.
Synthetic Biologics Inc (NYSEMKT:SYN)’s shares jumped 5.87% to $7.76, during the current trading session Wednesday’s, hitting its highest level.
Synthetic Biologics, Inc. (SYN), this week presented initial data that support the Company’s development of a platform of therapeutics designed to protect the microbiome from carbapenems, a class of beta-lactam antibiotics. The data were presented in a poster at the 115th General Meeting of the American Society of Microbiology (ASM) in New Orleans, LA.)
Beta-lactam antibiotics are a mainstay in hospital infection administration. However, antibiotics have the potential to cause unintended harmful effects within the gastrointestinal (GI) tract, counting disruption of the natural balance of the gut microbiome, leading to 1.1 million C. difficile infectionsi and 30,000 C. difficile-related deathsii in the United States each year. SYN-004 is the Company’s candidate therapy designed to degrade certain intravenous (IV) beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea (AAD) and secondary antibiotic-resistant infections. SYN-004 is designed to protect the microbiome from two classes of beta-lactam antibiotics, penicillins and cephalosporins.
During ASM, the “Development of Therapeutic Agents that Protect the Colonic Microflora from Beta-Lactam Antibiotics for the Prevention of Clostridium difficile Infection” poster summarized the identification of a novel pipeline beta-lactamase, P2A, which has the ability to protect the gut microbiome from a third class of beta-lactam antibiotics, carbapenems. Adding P2A to the franchise platform expands Synthetic Biologics’ intellectual property claims to cover all three beta-lactam antibiotic classes, penicillins, cephalosporins, and carbapenems.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
In a mid-morning trade, AuRico Gold Inc (NYSE:AUQ)‘s shares drop -2.37%, to $3.29.
AuRico Gold Inc (AUQ) declared that Alamos and AuRico have been granted an interim order from the Ontario Superior Court of Justice (Commercial List) authorizing various matters, counting the holding of special meetings of Alamos and AuRico shareholders to consider the projected plan of arrangement (the “Arrangement”) to combine the two companies, and the mailing of the joint information circular.
The special meetings of Alamos and AuRico shareholders to consider the Arrangement will be held on June 24, 2015 at the offices of Fasken Martineau DuMoulin LLP, 333 Bay Street, 24th Floor, Toronto, Ontario, M5H 2T6. AuRico’s special meeting of shareholders will commence at 10:00 a.m. (Eastern Time) followed by Alamos’ special meeting of shareholders at 11:00 a.m. (Eastern Time). Shareholders of record as of the close of business on May 22, 2015 will be eligible to vote at the special meetings.
AuRico Gold Inc. operates as a gold producer with mines and projects in North America. Its principal projects comprise the Young-Davidson gold mine comprising of contiguous mineral leases and claims totaling 11,000 acres located in Northern Ontario, Canada; and the El Chanate mine comprising 22 mineral concessions that cover an area of about 4,618 hectares located in Sonora State, Mexico.
KBR, Inc. (NYSE:KBR), during its Wednesday’s current trading session gained 0.92% to $19.66.
KBR, Inc. (KBR) declared that Stuart Bradie, President and CEO, and Brian Ferraioli, Executive Vice President and CFO, will present at the Credit Suisse 2015 Engineering and Construction Conference on Thursday, June 4, 2015 at 10:50 a.m. Eastern Time (9:50 a.m. Central Time).
KBR, Inc. operates as an engineering, construction, and services company worldwide. The company operates through three segments: Technology & Consulting, Engineering & Construction, and Government Services. The Technology & Consulting segment offers various services and solutions, counting licensing, engineering and design, proprietary equipment, plant automation, catalysts, and related consulting services to hydrocarbons, chemicals, and fertilizer markets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
